Managing Editor:Peng Lyu Macrofocal multiple myeloma(MFMM)is a distinct entity within multiple myeloma(MM)characterized by the presence of multiple lytic bone lesions,with clonal plasma cells in the bone marrow accoun...Managing Editor:Peng Lyu Macrofocal multiple myeloma(MFMM)is a distinct entity within multiple myeloma(MM)characterized by the presence of multiple lytic bone lesions,with clonal plasma cells in the bone marrow accounting for<10%.1,2 The revised 2022 Chinese guidelines for the diagnosis and treatment of MM state:in patients with<10%clonal plasma cells in multi-site bone marrow aspirates,attention should be given to MFMM,characterized by single or multiple bone destructive lesions,often accompanied by involvement of surrounding soft tissues or lymph nodes.3 Research is limited regarding the long-term use of adoptive immunotherapy for the treatment of MFMM;as such,we report herein the case of an elderly patient diagnosed with MFMM who experienced severe chemotherapy side effects and subsequently underwent adoptive immunotherapy.Remarkably,the patient benefited from 14 years of treatment[Figure 1A].展开更多
基金supported by the National Key Research and Development Program of China(No.2021YFC2701700)the National Key Research and Development Program of China(No.2021YFC2701704)the Military Logistics Research Project Health Special Project(No.NCRCG-PLAGH-20230010).
文摘Managing Editor:Peng Lyu Macrofocal multiple myeloma(MFMM)is a distinct entity within multiple myeloma(MM)characterized by the presence of multiple lytic bone lesions,with clonal plasma cells in the bone marrow accounting for<10%.1,2 The revised 2022 Chinese guidelines for the diagnosis and treatment of MM state:in patients with<10%clonal plasma cells in multi-site bone marrow aspirates,attention should be given to MFMM,characterized by single or multiple bone destructive lesions,often accompanied by involvement of surrounding soft tissues or lymph nodes.3 Research is limited regarding the long-term use of adoptive immunotherapy for the treatment of MFMM;as such,we report herein the case of an elderly patient diagnosed with MFMM who experienced severe chemotherapy side effects and subsequently underwent adoptive immunotherapy.Remarkably,the patient benefited from 14 years of treatment[Figure 1A].
